Koen C. Van Son

Amsterdam, NH, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Two-step care pathways for advanced MASLD in primary and hospital care: A multicenter study.

Two-step care pathways for advanced MASLD in primary and hospital care: A multicenter study.

Journal: Hepatology communications

Published: December 03, 2025

Two-step care pathways for advanced MASLD in primary and hospital care: A multicenter study.

Two-step care pathways for advanced MASLD in primary and hospital care: A multicenter study.

Journal: Hepatology communications

Published: December 03, 2025

Combination of quantitative MRI and laboratory markers for the detection and staging of metabolic dysfunction-associated steatotic liver disease.

Combination of quantitative MRI and laboratory markers for the detection and staging of metabolic dysfunction-associated steatotic liver disease.

Journal: European radiology

Published: July 25, 2025

Increasing incidence and changing trends in etiology & survival rates in HCC in a European cohort.

Increasing incidence and changing trends in etiology & survival rates in HCC in a European cohort.

Journal: JHEP reports : innovation in hepatology

Published: June 16, 2025

Increasing incidence and changing trends in etiology & survival rates in HCC in a European cohort.

Increasing incidence and changing trends in etiology & survival rates in HCC in a European cohort.

Journal: JHEP reports : innovation in hepatology

Published: June 16, 2025

Prognostic Value of the TLM3 Biomarker Panel for Early Fibrosis Development in MASLD Within the General Population.

Prognostic Value of the TLM3 Biomarker Panel for Early Fibrosis Development in MASLD Within the General Population.

Journal: Liver international : official journal of the International Association for the Study of the Liver

Published: January 15, 2025

Validation of the enhanced liver fibrosis (ELF)-test in heparinized and EDTA plasma for use in reflex testing algorithms for metabolic dysfunction-associated steatotic liver disease (MASLD).

Validation of the enhanced liver fibrosis (ELF)-test in heparinized and EDTA plasma for use in reflex testing algorithms for metabolic dysfunction-associated steatotic liver disease (MASLD).

Journal: Clinical chemistry and laboratory medicine

Published: March 14, 2024

Prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) in a middle-aged population with overweight and normal liver enzymes, and diagnostic accuracy of noninvasive proxies.

Prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) in a middle-aged population with overweight and normal liver enzymes, and diagnostic accuracy of noninvasive proxies.

Journal: Medicine

Published: January 05, 2024

Development of a novel non-invasive biomarker panel for hepatic fibrosis in MASLD.

Development of a novel non-invasive biomarker panel for hepatic fibrosis in MASLD.

Journal: Nature communications

Published: August 23, 2023

Intrapancreatic fat deposition is unrelated to liver steatosis in metabolic dysfunction-associated steatotic liver disease.

Intrapancreatic fat deposition is unrelated to liver steatosis in metabolic dysfunction-associated steatotic liver disease.

Journal: JHEP reports : innovation in hepatology

Published: June 08, 2023

A global survey of health care workers' awareness of non-alcoholic fatty liver disease: The AwareNASH survey.

A global survey of health care workers' awareness of non-alcoholic fatty liver disease: The AwareNASH survey.

Journal: United European gastroenterology journal

Published: April 12, 2023

Non-Parenchymal Cells and the Extracellular Matrix in Hepatocellular Carcinoma in Non-Alcoholic Fatty Liver Disease.

Non-Parenchymal Cells and the Extracellular Matrix in Hepatocellular Carcinoma in Non-Alcoholic Fatty Liver Disease.

Journal: Cancers

Published: December 23, 2022

Showing 1-12 of 14

Last Updated: 09/26/2026